Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ionis Pharmaceuticals (IONS) -- Ignore unavailable to you. Want to Upgrade?

To: james who wrote (1372)	12/5/1997 2:39:00 AM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 4676

James: >>I give mAB a better chance. Because I have not read anything about the half-life of ICAM-1 protein (lazy), any data? If it's long, AS might not generate a bottle-neck. Which might hold for AS/mAB in all cases targeting extracellular proteins. Sorry for posting this kind of counter-opinion on ISIP thread.<< No problem. Thread without counter-opinion is not thread. Many do like mAB (actually they reemerge in last 12-16 months) and for some indication I do prefer them. Max (PB) with his comments on many thread helped me a loot. When is chronic disease target, you don't need bottle-neck, and if it isn't very specific it means a great chance for side effects. For instance ENBREL have serious problem with pulmonary infections, even pneumonia may accrue. Regards the AS only future will show true story. For instance Dr. Crooke announce that in 98 Isis will be focused on cancer ASs. Like they are abounding ICAM-1 AS. I think that street is wrong. Once compound enter late stage clinical trials, company has lower duty. They are paying principal investigator and outsade service for majority work. Isis focus in cancer AS means that they will spent great deal of time and in-house source to develop (preclinical study) new and better AS for this disease. mz